# Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients

> **NCT03857165** · PHASE1 · COMPLETED · sponsor: **Shanton Pharma Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Gout, Hyperuricemia

## Interventions

- **DRUG:** SAP-001

## Key facts

- **NCT ID:** NCT03857165
- **Lead sponsor:** Shanton Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-24
- **Primary completion:** 2019-06-02
- **Final completion:** 2019-10-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03857165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03857165, "Placebo Controlled, Dose Escalation Study to Evaluate Safety, Pharmacokinetics & Efficacy of SAP-001 in Gout Patients". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03857165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*